FDA approves record number of drugs in 2018; significant amount developed in Cambridge & Boston
2018 was a banner year as the FDA approved a record number of drugs breaking the previous record which was set in 2017 at 46.
April 09, 2019
- 2018 was a banner year as the FDA approved a record number of drugs breaking the previous record which was set in 2017 at 46.
- Of the 59 drugs approved last year, 23 came from companies who have a significant research in Cambridge, Boston, and the suburbs.
- Shire, Novartis, and Vertex, who combined occupy 3.5 million square feet of office and lab across Greater Boston each got a drug in the pipeline approved with Shire notching two. Pfizer, who occupies about 700,000 square feet between Cambridge and its manufacturing facilities in Andover, led all pharmaceutical companies receiving approval from the federal government for four drugs.
- Also notably, Alnylam, who is headquartered in Kendall Square, became the first company ever to receive an approval for a drug that uses RNAi technology.
You may also like
Shifts in the way people live, work and shop in a post pandemic world have forever impacted the industrial real estate sector
Chestnut and Walnut Street retail visits drop precipitously in Philadelphia during COVID-19 pandemic
Pressure from distressed New York retailers has softened landlord sentiment, allowing for lease restructurings